Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
Titel:
Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
Auteur:
André, Thierry Falcone, Alfredo Shparyk, Yaroslav Moiseenko, Fedor Polo-Marques, Eduardo Csöszi, Tibor Campos-Bragagnoli, Arinilda Liposits, Gabor Chmielowska, Ewa Aubel, Paul Martín, Lourdes Fougeray, Ronan Amellal, Nadia Saunders, Mark P